Nika Duan

We're excited to partner with A. J. Loiacono and the Judi Health (formerly Capital Rx) team as they close on $400M in new funding. Judi's vision for Unified Claims - across both medical and pharmacy - are an enormous step in the right direction in addressing some of the most pressing issues in healthcare infrastructure.

31

6 Comments

Clinical trials have historically excluded the patients who need them most. That’s exactly what Dr. Hala Borno and the Trial Library team are making clinical trials a care option for every patient. Through How Women Invest Fund III, we’re proud to join SemperVirens VC, NEXT Ventures, Sanofi Ventures, Lux Capital, Civilization Ventures, Overwater Ventures and others in Trial Library’s $10M Series A. As an investor, I’m looking for companies that realign incentives across an entire system: patients, providers, payers, and biopharma. Trial Library does exactly that, making innovation accessible while reducing healthcare costs for everyone. Thrilled to welcome Hala and the team to the How Women Invest Fund III portfolio.  Read more: https://lnkd.in/gEgtGN9p

22

4 Comments

Matt Holt, former New Mountain Capital executive, is exploring a $30 billion deal to combine five health tech startups into a single platform called Thoreau. The venture would set out to simplify and integrate services across payers, providers and data — and if completed, it would rank among the largest private equity-backed health tech companies ever. Time will tell if this massive consolidation ever gets completed or translates into real value — or if it's just another bet on scale.

46

3 Comments

Bret Anderson has spent 20 years working with hospitals and health systems on the economics of care delivery. His read on IVF was straight-forward on the Inside Reproductive Health podcast with Griffin Jones: "Over the last decade or so, there has probably been a greater focus on the revenue side and less so on the cost side. I think that the next five to ten years are going to be much more focused on the economics of the operating model," Anderson said. That's exactly what we found building the activity-based costing framework published in the Journal of Assisted Reproduction and Genetics last December. The revenue side of IVF is well understood. Coverage mandates are expanding. Managed care is rising. What isn't well understood is what it actually costs to deliver a cycle — down to the activity level, by procedure type, by egg count, by lab scale. The payers are going to figure this out. The question is whether clinic operators figure it out first? Full paper and episode link in comments. #IVFEconomics #FertilityBusiness #ActivityBasedCosting #JARG Conceivable Life Sciences

26

3 Comments